ClinConnect ClinConnect Logo
Search / Trial NCT06900153

Parenting and CAH - 21-hydroxylase Deficiency

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 21, 2025

Trial Information

Current as of April 29, 2025

Not yet recruiting

Keywords

Congenital Adrenal Hyperplasia Due To 21 Hydroxylase Deficiency Fertility Pregnancy Outcomes Pregnancy Related Hormonal Substitution Parental Project

ClinConnect Summary

This clinical trial is studying how the genetic condition known as congenital adrenal hyperplasia (CAH), specifically the 21-hydroxylase deficiency (21OHD) type, affects women, particularly in terms of their sexuality, fertility, and pregnancy outcomes. CAH is caused by a problem with a gene that helps the body produce certain hormones. The trial aims to gather more information about how this condition impacts women and their experiences, as there is currently limited data available.

To be eligible for this trial, participants must be women aged 18 or older who have been genetically confirmed to have 21-hydroxylase deficiency. They should also be able to understand and agree to participate in the research. Unfortunately, women who do not speak French or who are under legal protection cannot join the study. Those who participate can expect to share their experiences and possibly receive information that could help improve care for others with this condition. Overall, this trial hopes to shed light on important aspects of living with CAH and to improve the support and treatment options available for affected women.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Patients aged 18 or over
  • Patients with HCS due to 21-hydroxylase deficiency, confirmed genetically
  • Patients who have been informed and do not object to participating in the research
  • Exclusion Criteria:
  • Patients who do not speak French
  • Patients who are not affiliated to a social security scheme or who are not entitled to it
  • Patients under legal protection, or under guardianship or trusteeship.

About Assistance Publique Hôpitaux De Paris

Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported